Background <p>Androgenetic alopecia (AGA) is the most common cause of hair loss, and current pharmacotherapies have limitations. Autologous platelet-derived therapies, including PRP, its standardized derivative PRGF, and other growth factor concentrates (GFC), have emerged as regenerative options, but differences in preparation and mixed clinical evidence remain.</p> Methodology <p>Following PRISMA guidelines, seven databases were searched for randomized and non-randomized studies on intralesional growth factor injections for AGA. Outcomes included hair density, thickness, satisfaction, and adverse events, with quality assessed using RoB2, MINORS, and MMS tools.</p> Results <p>Twelve studies (745 patients) were included. GFC showed progressive hair density gains from 19.6 hairs/cm² at 1 month to 57.1 at 12 months, while PRP increased density by 34.4 at 6 months and 42.0 at 12 months. GFC also improved thickness (5.19–22.03 µm) with 94.3% patient satisfaction. Adverse events were mild, but RCTs had a high risk of bias, and non-randomized studies showed serious to critical bias.</p> Conclusion <p>Autologous growth factor injections appear safe and improve hair density, thickness, and patient satisfaction over 12 months, especially with newer concentrates. However, high risk of bias, substantial heterogeneity (I² &gt; 90%), and non-standardized protocols limit the evidence, making findings hypothesis-generating until larger, standardized, double-blind trials with long-term follow-up are conducted.</p> Level of Evidence III <p>This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors &#xa0;<a href="http://www.springer.com/00266">www.springer.com/00266</a>.</p>